Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñÀΰ­¾ÏÀÇ Ä¡·á¿¡¼­ µ¿½ÃÂ÷µîÁ¶»ç°¡¼ÓÄ¡·á¸¦ Àû¿ëÇÑ Á¦1»ó/2»ó ¿¬±¸ÀÇ ¿¹ºñÀû °á°ú Preliminary Results of Phase I/II Study of Simultaneous Modulated Accelerated (SMART) for Nasopharyngeal Carcinoma

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2006³â 24±Ç 1È£ p.1 ~ 10
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÚÁøÈ«/Park JH ÀÌ»ó¿í/¹é±Ý¹®/À̺´¿ë/ÃÖÀº°æ/¾È½Âµµ/½Å¼º¼ö/±èÁ¤ÈÆ/±è»óÀ±/À̺ÀÀç/³²¼ø¿­/ÃÖ½ÂÈ£/±è¼º¹è/¹Ú¼ºÈ£/±èÁ¾ÈÆ/Lee SW/Back GM/Yi BY/Choi EK/Ahn SD/Shin SS/Kim JH/Kim SY/Lee BJ/Nam SY/Choi SH/Kim SB/Park SH/Kim JH

Abstract

¸ñ Àû: ºñÀΰ­¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î ½ÃÇàÇÑ µ¿½ÃÂ÷µîÁ¶»ç°¡¼ÓÄ¡·á(simultaneous modulated accelerated radiation therapy, SMART)¸¦ ÀÌ¿ëÇÑ ¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á(intensity modulated radiation therapy, IMRT)ÀÇ ¿¹ºñÀû ÀÓ»ó°á°ú¸¦ º¸°íÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 2001³â 9¿ùºÎÅÍ 2003³â 12¿ù±îÁö ¼­¿ï¾Æ»êº´¿ø¿¡¼­ ±ÙÄ¡Àû ¸ñÀûÀÇ µ¿½ÃÂ÷µîÁ¶»ç°¡¼ÓÄ¡·á¸¦ ½ÃÇà¹ÞÀº 20¸íÀÇ ºñÀüÀ̼º ºñÀΰ­¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î ÀüÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. IMRT´Â ¡°step and shoot¡± SMART¸¦ »ç¿ëÇÏ¿© ½ÃÇàµÇ¾úÀ¸¸ç, °¢°¢ À°¾ÈÀûÁ¾¾çüÀû(gross tumor volume, GTV)¿¡ 72 Gy (2.4 Gy/day), ºñÀΰ­°ú ÀüÀ̼º ¸²ÇÁÀýºÎÀ§(metastatic nodal station) µîÀ» Æ÷ÇÔÇÏ´Â ÀÓ»óÇ¥ÀûüÀû 1 (Clinical target volume 1, CTV1)¿¡ 60 Gy (2.0 Gy/day), ±×¸®°í ÀÓ»óÀûÀ¸·Î ÀüÀÌ°¡ ¾ø´Â °æºÎ ºÎÀ§¸²ÇÁÀýÀ» Æ÷ÇÔÇÏ´Â ÀÓ»óÇ¥ÀûüÀû 2 (clinical target volume 2, CTV2)¿¡ 46 Gy (2 Gy/day)¸¦ Á¶»çÇÏ¿´´Ù. 18¸íÀÇ È¯ÀÚ´Â ÁÖ´ç 1ȸÀÇ cisplatin È­Çпä¹ýÀ» ½ÃÇà¹Þ¾Ò´Ù.

°á °ú: ¿¬±¸´ë»ó¿¡ Æ÷ÇÔµÈ È¯ÀÚÀÇ ÃßÀû°üÂû ±â°£ÀÇ Áß¾Ó°ªÀº 27°³¿ùÀ̾ú´Ù. 19¸íÀÇ È¯ÀÚ´Â Ä¡·á Áß´Ü ¾øÀÌ °èȹµÈ Ä¡·á¸¦ ¼º°øÀûÀ¸·Î ¼öÇàÇÏ¿´À¸³ª, 1¸íÀº °íµµÀÇ Àεο°°ú ¿µ¾çºÒ·®À¸·Î 2ÁÖ°£ Ä¡·á°¡ ÁߴܵǾú´Ù. Ä¡·á ±â°£ Áß ±Þ¼º µ¶¼ºÀº RTOG 3µµÀÇ Á¡¸·¿°°ú Àεο°ÀÌ °¢°¢ 5¸í(25%)°ú 9¸í(45%)¿¡¼­ °üÂûµÇ¾ú´Ù. 7¸í(35%)Àº 10% ÀÌ»óÀÇ Ã¼Áß °¨¼Ò¸¦ º¸¿´À¸¸ç 11¸í(55%)Àº Á¤¸Æ¼ö¾×¿ä¹ý ȤÀº °æ°ü¿µ¾ç¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ¿´´Ù. ¸¸¼º µ¶¼º¿¡¼­ 3±Þ ÀÌ»óÀÇ ±¸°­°ÇÁ¶ÁõÀº °üÂûµÇÁö ¾Ê¾Ò´Ù. Ä¡·á ¹ÝÀÀÀº ¸ðµç ȯÀÚ¿¡¼­ ¿ÏÀü°üÇظ¦ º¸¿´°í, ¿ø°ÝÀüÀÌ¿Í ±¹¼ÒÀç¹ßÀÌ °¢°¢ 2¸í°ú 1¸í¿¡¼­ °üÂûµÇ¾ú´Ù.

°á ·Ð: SMART¸¦ »ç¿ëÇÑ IMRT¸¦ µµÀÔÇÏ¿© ÀÓ»óÀûÀ¸·Î³ª ¼±·®ÃøÁ¤»ó ÀÌÇϼ±ÀÇ ±â´É º¸Á¸ÀÌ °¡´ÉÇÏ¿´À¸¸ç, ¶ÇÇÑ »ý¹°ÇÐÀûÀ¸·Î ´õ¿í È¿°úÀûÀÏ °ÍÀ¸·Î »ý°¢µÇ¾ú´Ù. ÇâÈÄ Á¤È®ÇÑ Á¾¾ç¾ïÁ¦ È¿°ú¿Í ¸¸±â µ¶¼ºÀ» ¾Ë±â À§Çؼ­´Â Ãß°¡ÀûÀÎ ¿¬±¸´ë»ó°ú ÃßÀû°üÂûÀÌ ÇÊ¿äÇÏ´Ù°í »ý°¢ÇÑ´Ù.

Purpose: To present preliminary results of intensity-modulated radiotherapy (IMRT) using the simultaneous modulated accelerated radiation therapy (SMART) boost technique in patients with nasopharyngeal carcinoma (NPC).

Materials and Methods: Twenty patients who underwent IMRT for non-metastatic NPC at the Asan Medical Center between September 2001 and December 2003 were prospectively evaluated. IMRT was delivered using the ¡°step and shoot¡± SMART technique at prescribed doses of 72 Gy (2.4 Gy/day) to the gross tumor volume (GTV), 60 Gy (2 Gy/day) to the clinical target volume (CTV) and metastatic nodal station, and 46 Gy (2 Gy/day) to the clinically negative neck region. Eighteen patients also received concurrent chemotherapy using cisplatin once per week.

Results: The median follow-up period was 27 months. Nineteen patients completed the treatment without interruption; the remaining patient interrupted treatment for 2 weeks owing to severe pharyngitis and malnutrition. Five patients (25%) had RTOG grade 3 mucositis, whereas nine (45%) had grade 3 pharyngitis. Seven patients (35%) lost more than 10% of their pretreatment weight, whereas 11 (55%) required intravenous fluids and/or tube feeding. There was no grade 3 or 4 chronic xerostomia. All patients showed complete response. Two patients had distant metastases and loco-regional recurrence, respectively.

Conclusion: IMRT using the SMART boost technique allows parotid sparing, as shown clinically and by dosimetry, and may also be more effective biologically. A larger population of patients and a longer follow-up period are needed to evaluate ultimate tumor control and late toxicity.

Å°¿öµå

µ¿½ÃÈ­Çйæ»ç¼±Ä¡·á;¼¼±âÁ¶Àý¹æ»ç¼±Ä¡·á;ºñÀΰ­¾Ï;Concurrent chemoradiotherapy;Intensity modulated radiotherapy;Nasopharyngeal carcinoma

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS